Based on these facts, we estimated that CAV1 could improve PCa diagnostics, thus, the aim of this study is to explore CAV1 methylation of cfDNA in liquid biopsy samples, blood, and semen, as a potential minimally invasive marker or as part of a diagnostic panel to distinguish PCa from BPH or indolent from clinically significant PCa. This evidence concerns the gene CAV1 and posterior cortical atrophy.